Zura Bio (NASDAQ:ZURA) Trading Up 11.8% – Should You Buy?

Zura Bio Limited (NASDAQ:ZURA)’s stock price rose 11.8% during trading on Monday . The company traded as high as $5.95 and last traded at $6.5430. Approximately 257,271 shares changed hands during mid-day trading, a decline of 69% from the average daily volume of 830,721 shares. The stock had previously closed at $5.85.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ZURA shares. Guggenheim raised their price target on Zura Bio from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Wedbush increased their price objective on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research note on Monday, July 6th. Finally, William Blair started coverage on Zura Bio in a report on Wednesday, July 8th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.00.

Zura Bio Stock Performance

The company has a market cap of $597.85 million, a PE ratio of -5.57 and a beta of -0.02. The stock’s 50-day simple moving average is $5.21 and its 200 day simple moving average is $5.39.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Tuesday, June 30th. The company reported ($0.21) EPS for the quarter. On average, sell-side analysts predict that Zura Bio Limited will post -0.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

A number of large investors have recently modified their holdings of ZURA. Bank of America Corp DE boosted its stake in shares of Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after buying an additional 9,966 shares in the last quarter. AQR Capital Management LLC purchased a new position in Zura Bio in the first quarter worth $72,000. JPMorgan Chase & Co. raised its position in Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,052,732 shares in the last quarter. Jane Street Group LLC acquired a new stake in Zura Bio in the second quarter valued at $113,000. Finally, UBS Group AG lifted its holdings in Zura Bio by 878.3% in the third quarter. UBS Group AG now owns 305,329 shares of the company’s stock valued at $1,322,000 after acquiring an additional 274,118 shares during the period. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.